KR900016469A - 항종양 항생제 케다르시딘(kedarcidin) - Google Patents

항종양 항생제 케다르시딘(kedarcidin) Download PDF

Info

Publication number
KR900016469A
KR900016469A KR1019890004782A KR890004782A KR900016469A KR 900016469 A KR900016469 A KR 900016469A KR 1019890004782 A KR1019890004782 A KR 1019890004782A KR 890004782 A KR890004782 A KR 890004782A KR 900016469 A KR900016469 A KR 900016469A
Authority
KR
South Korea
Prior art keywords
kedarsidine
strain
antibiotic
kedarcidin
produced
Prior art date
Application number
KR1019890004782A
Other languages
English (en)
Other versions
KR970010137B1 (ko
Inventor
호프스태드 산드라 제이
에이. 매트슨 제임스
램 킨 에스
포렌자 살바토르
에이. 부쉬 제임스
도미따 고지
Original Assignee
아이삭 자아코브스키
브리스톨-마이어즈 컴페니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이삭 자아코브스키, 브리스톨-마이어즈 컴페니 filed Critical 아이삭 자아코브스키
Publication of KR900016469A publication Critical patent/KR900016469A/ko
Application granted granted Critical
Publication of KR970010137B1 publication Critical patent/KR970010137B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음.

Description

항종양 항생제 케다르시딘(KEDARCIDIN)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
첨부된 도면은 항생제 케다르시딘의 UV 스펙트럼.

Claims (8)

  1. 다음과 같이 특징지워진 항생제 케다르시딘 : (a)모양 : 담황색 고체, (b) 분자량 : SDS-폴리아크릴아미드 겔전기 영동 방법에 의한 12,400 dalton, 겔여과/HPLC 방법으로서 17,000 delton, (c)UV스펙트럼 : 첨부된 도면에 도시된 것과 실질적으로 같은것, (d) 등전점 3.65, 그리고 (e)다음의 아미노산 배열을 가진 폴리펩티드로 구성됨.
    이며 상기 배열에서 X는 H-ala-ser, H-ser,및 H로 이루어진 기로부터 선택됨.
  2. 침수호기 조건하에 탄소 및 질소 동화원을 함유한 배지속에서 Streptoalloteichus인 케다르시딘 생성 균주를 배양시키고, 배양된 즙으로부터 상기 항생제를 회수하는 것으로 이루어진 항생제 케다르시딘을 제조하는 방법.
  3. 제2항에 있어서, 상기 생성 균주가 균주 L585-6,ATCC53650임을 특징으로 하는 재조방법.
  4. 미생물 Streploalloteichus sp. nov., 균주 L585-6, ATCC 53650의 생물학적 순수 배양체.
  5. 케다르시딘의 종양 억제량 및 약리학적 허용가능한 담체로 이루어진 종양 억제제 조성물.
  6. 케다르시딘의 종양 억제 유효량을 상기 종양-운반숙주에 투여하는 것으로 이루어진 케다르시딘에 과민한 포유류 숙주내의 종양 성장을 억제하는 방법.
  7. 다음단계로 이루어진 방법에 의하여 제조된 항생제 케다르시딘. a. 침수호기 조건하에 탄소 및 질소동화원을 함유한 배지속에서 Streptoalloteichus 인 케다르시딘 생성균주를 배양하는 단계, 및 b. 배양된 즙으로부터 상기 항생제를 회수하는 단계.
  8. 상기 생성 균주가 균주 L58S-5, ATCC 53650임을 특징으로하는 제7항의 방법에 의하여 제조된 항생제 케다르시딘.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890004782A 1988-04-12 1989-04-11 항종양 항생제 케다르시딘(kedarcidin) KR970010137B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18051988A 1988-04-12 1988-04-12
US182519 1988-04-12
US180,159 1988-04-12
US07/323,001 US5001112A (en) 1988-04-12 1989-03-17 Antitumor antibiotic kedarcidin
US323,001 1989-03-17

Publications (2)

Publication Number Publication Date
KR900016469A true KR900016469A (ko) 1990-11-13
KR970010137B1 KR970010137B1 (ko) 1997-06-21

Family

ID=26876396

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890004782A KR970010137B1 (ko) 1988-04-12 1989-04-11 항종양 항생제 케다르시딘(kedarcidin)

Country Status (24)

Country Link
US (1) US5001112A (ko)
EP (1) EP0337430B1 (ko)
JP (1) JP2850132B2 (ko)
KR (1) KR970010137B1 (ko)
CN (1) CN1034589C (ko)
AT (1) ATE101653T1 (ko)
AU (1) AU623641B2 (ko)
CA (1) CA1338262C (ko)
CY (1) CY1849A (ko)
DE (1) DE68913063T2 (ko)
DK (1) DK174751B1 (ko)
ES (1) ES2061760T3 (ko)
FI (1) FI93969C (ko)
HK (1) HK83195A (ko)
HU (1) HU201119B (ko)
IE (1) IE62912B1 (ko)
IL (1) IL89896A0 (ko)
MY (1) MY105842A (ko)
NO (1) NO174474C (ko)
NZ (1) NZ228672A (ko)
PL (1) PL161004B1 (ko)
PT (1) PT90252B (ko)
SG (1) SG30654G (ko)
YU (1) YU73989A (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143906A (en) * 1991-09-26 1992-09-01 Bristol-Myers Squibb Company Kedarcidin antitumor chromophore and pharmaceutical composition containing same
WO2003062458A2 (en) * 2002-01-24 2003-07-31 Ecopia Biosciences Inc. Method, system and knowledge repository for identifying a secondary metabolite from a microorganism
AU2009309416B2 (en) * 2008-10-27 2015-05-28 Glaxosmithkline Biologicals S.A. Purification method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS519837B2 (ko) * 1974-03-29 1976-03-30
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
JPS6017206B2 (ja) * 1977-03-24 1985-05-01 浩 前田 ネオカルチノスタチン誘導体の製造法
JPS56113791A (en) * 1980-02-15 1981-09-07 Kaken Pharmaceut Co Ltd Novel antibiotic and its preparation
JPS57206693A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Protein an-7d
JPS59184135A (ja) * 1983-04-04 1984-10-19 Teijin Ltd グリセリンピログルタミン酸エステル類を含有する医薬品組成物

Also Published As

Publication number Publication date
SG30654G (en) 1995-09-01
ATE101653T1 (de) 1994-03-15
NO174474B (no) 1994-01-31
CA1338262C (en) 1996-04-23
PL161004B1 (pl) 1993-05-31
DE68913063D1 (de) 1994-03-24
FI93969B (fi) 1995-03-15
CN1037735A (zh) 1989-12-06
PT90252A (pt) 1989-11-10
DK173589A (da) 1989-10-13
PT90252B (pt) 1994-07-29
NZ228672A (en) 1990-07-26
DK174751B1 (da) 2003-10-20
EP0337430B1 (en) 1994-02-16
CY1849A (en) 1996-03-08
NO891462L (no) 1989-10-13
EP0337430A3 (en) 1991-07-24
HU201119B (en) 1990-09-28
FI93969C (fi) 1995-06-26
KR970010137B1 (ko) 1997-06-21
CN1034589C (zh) 1997-04-16
DK173589D0 (da) 1989-04-11
JP2850132B2 (ja) 1999-01-27
IE62912B1 (en) 1995-03-08
YU73989A (en) 1991-04-30
DE68913063T2 (de) 1994-06-09
NO174474C (no) 1998-06-09
HK83195A (en) 1995-06-01
PL278782A1 (en) 1989-12-27
ES2061760T3 (es) 1994-12-16
HUT50880A (en) 1990-03-28
AU623641B2 (en) 1992-05-21
IL89896A0 (en) 1989-12-15
IE891157L (en) 1989-10-12
AU3272889A (en) 1989-10-19
FI891710A0 (fi) 1989-04-11
NO891462D0 (no) 1989-04-10
JPH01317396A (ja) 1989-12-22
EP0337430A2 (en) 1989-10-18
MY105842A (en) 1995-01-30
US5001112A (en) 1991-03-19
FI891710A (fi) 1989-10-13

Similar Documents

Publication Publication Date Title
DE3486452T2 (de) Superoxiddismutase und deren Expression in Mikroorganismen
KR910009729A (ko) 신규한 폴리펩티드 화합물과 그 제조방법
KR850005454A (ko) 환상 폴리펩타이드의 제조방법
KR950000890A (ko) 약리학적 작용을 갖는 악티노플레인스 종으로부터의 리포펩타이드, 이의 제조방법 및 용도
NO964754L (no) DNA-kjede anvendelig i ökning av karotenoid utbytte
KR890002214A (ko) 데만노실 테이코플라닌 유도체
KR900016469A (ko) 항종양 항생제 케다르시딘(kedarcidin)
KR900003206A (ko) 항생물질 머사시딘, 이의 제조방법 및 약제로서의 이의 용도
DK165757C (da) Biologisk ren kultur af mikroorganismen streptomyces roseosporus nrrl 15998 samt en fremgangsmaade til fremstilling af det antibiotisk virksomme a-21978c kompleks eller en eller flere af dettes faktorer co' c1' c2' c3' c4' og c5' under anvendelse af mikroorganismen
DZ658A1 (fr) Antibiotiques produits par kibdelosporagium aridumet leur préparation.
KR870002253A (ko) 펩타이드 항생제
Toguri et al. Synthesis of carbonic anhydrase with messenger RNA isolated from the cells of Chlamydomonas reinhardtii Dangeard C‐9 grown in high and low CO2
AU603545B2 (en) Media for increased yield of protein free of N-terminal methionine from recombinant escherichia coli
KR860007376A (ko) 인터로이킨-2의 제조방법
KR910002457A (ko) 항 비루스 항생제 bu-3889v
KR840005484A (ko) 항종양 항생물질의 제조방법
DE68927997D1 (de) Verfahren zum regeln des norleucingehalts in polypeptiden
EP0067038B1 (en) High molecular antitumor antibiotics an-7d
DE730028T1 (de) Neuartige Cholesterinoxidase
KR900018384A (ko) 항생제 아라노로신, 이의 미생물학적 제조방법 및 이의 약제로서의 용도
KR900009997A (ko) 스트렙토마이세스 가수가엔시스 kccb 101 및 이를 이용한 농용항생물질의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20071010

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee